OraSure Technologies INVESTOR PRESENTATION MARCH 2021 DNAgenoTeK" % Diversigen" novosanis Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are ...

Financial Data and Key Metrics Changes - In Q4 2020, net revenues increased by 27% to $62.9 million from $49.7 million in Q4 2019, primarily due to strong sales of COVID-19 molecular sample collection kits and increased international sales of HIV self-tests [30][31] - Net product and services revenues were $60.4 million, a 28% increase from Q4 2019 [31] - Gross profit percentage improved to 61% in Q4 2020 from 60% in Q4 2019 due to a better product mix [32] - Net income for Q4 2020 was $1.9 million or $0.03 per share, compared to $2.4 million or $0.04 per share in Q4 2019 [33] Business Line Data and Key Metrics Changes - The molecular business unit generated $40.3 million in revenues during Q4 2020, a 58% increase from Q4 2019, driven by $22.5 million in sales of COVID-19 molecular testing kits [31] - International sales of OraQuick HIV tests increased by 16% compared to Q4 2019, largely due to higher sales in Africa [32][39] - Total diagnostic revenues decreased by 7% in Q4 2020 compared to Q4 2019, but the HIV self-test segment showed resilience with a 16% growth [40][78] Market Data and Key Metrics Changes - The company expects the demand for COVID-19 testing to remain strong, with the Biden administration proposing $50 billion in spending to increase testing capacity [10][29] - The global need for testing is projected to be significant, especially with the emergence of new variants of the virus [11][12] - The company is focusing on expanding its market presence in both high-income and low-middle-income countries for COVID-19 testing [88] Company Strategy and Development Direction - The company is advancing three distinct COVID-19 testing opportunities: molecular testing, rapid antigen self-tests, and lab-based oral fluid antibody tests [13][22] - Plans to submit for Emergency Use Authorization (EUA) for both prescription and professional self-tests by the end of the month [8][20] - The company aims to leverage its strong balance sheet to pursue transformative business development opportunities while maximizing COVID-19 market potential [47][116] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the resilience of legacy businesses and the ongoing recovery in non-COVID segments [81] - The company anticipates continued growth in COVID-19 molecular revenues into 2021 and expects to emerge from the pandemic as a larger and more innovative entity [46][48] - Management highlighted the importance of testing as a key part of disease management even as vaccination efforts progress [12][29] Other Important Information - Cash and investments totaled $257.1 million at the end of 2020, providing a strong financial position for future growth [34] - The company is expanding manufacturing capacity to support the production of 120 million rapid antigen self-tests annually by Q2 2022 [27] Q&A Session Summary Question: Can you comment on the performance of the antigen test versus other at-home tests? - Management confirmed substantial progress and emphasized the simplicity of their test as a key advantage, with confidence in meeting FDA requirements [52][53] Question: What is the expected demand for antigen tests? - Management indicated strong expressions of interest from potential customers, although demand is not locked in until EUA approval is obtained [54][56] Question: Can you provide guidance on Q1 revenue expectations? - Management expects sequential growth in COVID-19 molecular collection devices but did not provide detailed guidance beyond Q1 due to regulatory uncertainties [62][63] Question: What is the timeline for international market access? - Management is focusing on higher-income countries first, with plans to expand to lower-middle-income countries later in the year [88] Question: How does the company view the opportunity for home testing? - Management sees significant potential in effortless diagnostics and plans to explore new opportunities in this area [102][104] Question: What is the status of the antibody test EUA submission? - Management is working on the necessary studies and aims to submit the EUA as soon as possible [106] Question: How does the company view its relationship with a major genomics customer going public? - Management remains optimistic about the relationship and sees it as a strong strategic partnership moving forward [109]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-16537 ORASURE TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-4370966 (State or Other Jurisdiction ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q3 2020 Earnings Conference Call November 4, 2020 5:00 PM ET Company Participants Jeanne Mell - Vice President of Corporate Communications Stephen Tang - President & Chief Executive Officer Roberto Cuca - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Frank Takkinen - Lake Street Capital Casey Woodring - JPMorgan Andrew Cooper - Raymond James Patrick Donnelly - Citigroup Jacob Johnson - Stephens Operator Good afternoon, everyone, and ...

OraSure Technologies INVESTOR PRESENTATION SEPTEMBER 2020 DNAgenoтeк" & Diversigen' novosanis UrSure Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements inclu ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q2 2020 Earnings Conference Call August 5, 2020 5:00 PM ET Company Participants Jeanne Mell - VP of Corporate Communications Steve Tang - President and Chief Executive Officer Roberto Cuca - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Jacob Johnson - Stephens Andrew Cooper - Raymond James Brandon Couillard - Jefferies Operator Good afternoon, everyone, and welcome to the OraSure Technologies 2020 Second Quarter Financial ...

OraSure Technologies INVESTOR PRESENTATION JULY 2020 DNAgenoTeK" % Diversigen" novosanis Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q1 2020 Earnings Conference Call May 6, 2020 5:00 PM ET Company Participants Stephen Tang - President, CEO & Director Roberto Cuca - CFO & Principal Accounting Officer Conference Call Participants Jacob Johnson - Stephens Inc. Andrew Cooper - Raymond James David Westenberg - Guggenheim Securities Brandon Couillard - Jefferies Operator Good afternoon, everyone, and welcome to the OraSure Technologies 2020 First Quarter Financial Results Conference Call and Simultaneou ...

OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2019 Earnings Conference Call February 19, 2020 5:00 PM ET Company Participants Stephen Tang - President, CEO & Director Roberto Cuca - CFO & Principal Accounting Officer Conference Call Participants John Hsu - Raymond James & Associates Brandon Couillard - Jefferies Operator Good afternoon, everyone, and welcome to the OraSure Technologies 2019 Fourth Quarter Financial Results Conference call and Simultaneous Webcast. As a reminder, today's conference is being re ...

OraSure Technologies Inc. (NASDAQ:OSUR) Q3 2019 Earnings Conference Call November 6, 2019 5:00 PM ET Company Participants Stephen Tang - President and Chief Executive Officer Roberto Cuca - Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies John Hsu - Raymond James Operator Good afternoon, everyone and welcome to the OraSure Technologies 2019 Third Quarter Financial Results Conference Call and Simultaneous Webcast. As a reminder, todayÂ's conference is being recorded. [Operat ...